gene editing
In Brief This Week: Ocugen, Acrivon, Myriad Genetics, Ariceum, Arbor Biotechnologies
News items for the week of Feb. 3, 2025.
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new approach to base editing.
HHS Calls Vertex's Case for Fertility Program a 'Distraction,' Urges Court to Rule in Its Favor
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run afoul of anti-kickback laws.
Jan 14, 2025
Dec 11, 2024
Nov 27, 2024
In Brief This Week: Hemogenyx, Intellia, Care Access
Sep 17, 2024